Preventing and managing vesicant chemotherapy extravasations

Journal of Supportive Oncology

Volumn 8, Issue 5, 2010, Pages 212-215

  Schulmeister, Lisa ^a  

^a MNS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; CHLORMETHINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EMLA; EPIRUBICIN; HYALURONIDASE; IDARUBICIN; INFUSION FLUID; MITOMYCIN; OXALIPLATIN; PACLITAXEL; RAZOXANE; SODIUM THIOSULFATE; VINBLASTINE; VINCRISTINE;

ARTICLE; CLINICAL FEATURE; COOLING; DEBRIDEMENT; DRUG SAFETY; EXTRAVASATION; HEALTH CARE POLICY; HUMAN; INTRAVENOUS ADMINISTRATION; PATIENT EDUCATION; PHLEBITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; RISK ASSESSMENT; SOMNOLENCE; SYMPTOM; VENOUS RETURN; WARMING; WOUND CARE;

EID: 78249267258     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suponc.2010.09.002     Document Type: Article

References (16)

1. Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol 2003; 14(suppl 3):iii26-iii30. [12821535]
2. Thakur JS, Chauhan CGS, Diwana VK, Chauhan DC, Thakur A. Extravasational side effects of cytotoxic drugs: a preventable catastrophe. Indian J Plast Surg 2008;41:145-150. [19753254]
3. Schulmeister L. Extravasation management. Semin Oncol Nurs 2007;23:184-190. [17693345]
4. Sauerland C, Engelking C, Wickham R, Corbi D. Vesicant extravasation part I: mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006;33:1134-1141. [1714396]
5. Jacobson JO, Polovich M, McNiff KK, et al. American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. Oncol Nurs Forum 2009;36:651-658. [19887353]
6. Jacobson JO, Polovich M, McNiff KK, et al. American Society of Clinical Oncology/ Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol 2009; 10:5469-5475. [19786650]
7. Schulmeister L. Vesicant chemotherapy extravasation antidotes and treatments. Clin J Oncol Nurs 2009;13:395-398. [19648094]
8. Smith L. National patient safety goal #13: patients' active involvement in their own care: preventing chemotherapy extravasation. Clin J Oncol Nurs 2009;13:233-234. [19349271]
9. Schulmeister L. Managing vesicant extravasations. Oncologist 2007;13:284-288. [18378538]
10. Schulmeister L. Extravasation. In: Polovich M, Whitford JM, Olsen M, eds. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice, 3rd ed. Pittsburgh: Oncology Nursing Society; 2009:105-111.
11. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004;15:858-862. [15151940]
12. Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol 2006;33:139-143. [16473651]
13. Dorr RT, Soble M, Alberts DS. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity. Cancer Chemother Pharmacol 1988;22:299-302. [3168143]
14. Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990;4:41-60. [2182147]
15. Schulmeister L. Totect: a new agent for treating anthracycline extravasation. Clin J Oncol Nurs 2007;11:387-395. [17623623]
16. Hasinoff BB. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Investig Drugs 2008;17:217-223. [18230055]